Arcturus Therapeutics Holdings Inc.
ARCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $458 | $840 | $449 | $974 |
| - Cash | $237 | $292 | $392 | $370 |
| + Debt | $29 | $30 | $95 | $69 |
| Enterprise Value | $250 | $578 | $151 | $673 |
| Revenue | $138 | $158 | $206 | $12 |
| % Growth | -12.3% | -23.3% | 1,564.8% | – |
| Gross Profit | $138 | $158 | $206 | $12 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$77 | -$24 | $14 | -$202 |
| % Margin | -55.9% | -15.3% | 6.7% | -1,631.7% |
| Net Income | -$81 | -$30 | $9 | -$204 |
| % Margin | -58.5% | -18.8% | 4.5% | -1,648% |
| EPS Diluted | -3 | -1.12 | 0.35 | -7.74 |
| % Growth | -167.9% | -420% | 104.5% | – |
| Operating Cash Flow | -$60 | -$18 | $32 | -$135 |
| Capital Expenditures | -$1 | -$3 | -$8 | -$3 |
| Free Cash Flow | -$60 | -$21 | $24 | -$138 |